Validated using a knockout cell line

Anti-Cyclin D1 antibody [EP272Y] (ab40754)


  • Product nameAnti-Cyclin D1 antibody [EP272Y]
    See all Cyclin D1 primary antibodies
  • Description
    Rabbit monoclonal [EP272Y] to Cyclin D1
  • Tested applicationsSuitable for: WB, IHC-P, ICC/IF, IPmore details
    Unsuitable for: Flow Cyt
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide corresponding to residues near the N-terminus (Human)

  • Positive control
    • WB: MCF-7 cell lysate. ICC/IF: MCF7 cells. IHC-P: Human kidney carcinoma and human hepatocellular carcinoma tissues.
  • General notes

    This product is a recombinant rabbit monoclonal antibody.


    Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

    A trial size is available to purchase for this antibody.



Our Abpromise guarantee covers the use of ab40754 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Detects a band of approximately 35 kDa (predicted molecular weight: 33 kDa).
IHC-P 1/250 - 1/500.
ICC/IF 1/50 - 1/100.
IP 1/10 - 1/100.
  • Application notesIs unsuitable for Flow Cyt.
  • Target

    • FunctionEssential for the control of the cell cycle at the G1/S (start) transition.
    • Involvement in diseaseNote=A chromosomal aberration involving CCND1 may be a cause of B-lymphocytic malignancy, particularly mantle-cell lymphoma (MCL). Translocation t(11;14)(q13;q32) with immunoglobulin gene regions. Activation of CCND1 may be oncogenic by directly altering progression through the cell cycle.
      Note=A chromosomal aberration involving CCND1 may be a cause of parathyroid adenomas. Translocation t(11;11)(q13;p15) with the parathyroid hormone (PTH) enhancer.
      Defects in CCND1 are a cause of multiple myeloma (MM) [MIM:254500]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving CCND1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus.
    • Sequence similaritiesBelongs to the cyclin family. Cyclin D subfamily.
    • Post-translational
      Phosphorylation at Thr-286 by MAP kinases is required for ubiquitination and degradation following DNA damage. It probably plays an essential role for recognition by the FBXO31 component of SCF (SKP1-cullin-F-box) protein ligase complex.
      Ubiquitinated, primarily as 'Lys-48'-linked polyubiquitination. Ubiquitinated by a SCF (SKP1-CUL1-F-box protein) ubiquitin-protein ligase complex containing FBXO4 and CRYAB (By similarity). Following DNA damage it is ubiquitinated by some SCF (SKP1-cullin-F-box) protein ligase complex containing FBXO31. Ubiquitination leads to its degradation and G1 arrest. Deubiquitinated by USP2; leading to stabilize it.
    • Cellular localizationNucleus.
    • Information by UniProt
    • Database links
    • Alternative names
      • AI327039 antibody
      • B cell CLL/lymphoma 1 antibody
      • B cell leukemia 1 antibody
      • B cell lymphoma 1 protein antibody
      • B-cell lymphoma 1 protein antibody
      • BCL 1 antibody
      • BCL-1 antibody
      • BCL-1 oncogene antibody
      • BCL1 antibody
      • BCL1 oncogene antibody
      • ccnd1 antibody
      • CCND1/FSTL3 fusion gene, included antibody
      • CCND1/IGHG1 fusion gene, included antibody
      • CCND1/IGLC1 fusion gene, included antibody
      • CCND1/PTH fusion gene, included antibody
      • CCND1_HUMAN antibody
      • cD1 antibody
      • Cyl 1 antibody
      • D11S287E antibody
      • G1/S specific cyclin D1 antibody
      • G1/S-specific cyclin-D1 antibody
      • Parathyroid adenomatosis 1 antibody
      • PRAD1 antibody
      • PRAD1 oncogene antibody
      • U21B31 antibody
      see all

    Anti-Cyclin D1 antibody [EP272Y] images

    • Predicted band size : 33 kDa

      Lane 1: Empty
      Lane 2: Wild type HAP1 whole cell lysate (20 µg)
      Lane 3: Cyclin D1 knockout HAP1 whole cell lysate (20 µg)
      Lane 4: A431 whole cell lysate (20 µg)

      Lanes 1 - 4: Merged signal (red and green). Green - ab40754 observed at 35 kDa. Red - loading control, ab18058, observed at 130 kDa.

      ab40754 was shown to recognize Cyclin D1 when HAP1 knockout samples were used, along with additional cross-reactive bands. Wild-type and HAP1 knockout samples were subjected to SDS-PAGE. ab40754 and ab18058 (Mouse anti Vinculin loading control) were incubated overnight at 4°C at 1000 dilution and 1/10000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed ab216776 secondary antibodies at 1/10000 dilution for 1 hour at room temperature before imaging.

    • ab40754 staining cyclin D1 in MCF7 cells treated with KN-93 (water soluble) (ab120980), by ICC/IF. Decrease in cyclin D1 expression correlates with increased concentration of KN-93 (water soluble), as described in literature.
      The cells were incubated at 37°C for 24 hours in media containing different concentrations of ab120980 (KN-93 (water soluble)) in DMSO, fixed with 100% methanol for 5 minutes at -20°C and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab40754 (1/100 dilution) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A goat anti-rabbit DyLight 488 goat anti-rabbit secondary antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.

    • Anti-Cyclin D1 antibody [EP272Y] (ab40754) at 1/2000 dilution + MCF-7 cell lysate at 10 µg

      Predicted band size : 33 kDa
      Observed band size : 36 kDa (why is the actual band size different from the predicted?)
    • Immunohistochemical analysis of paraffin-embedded human kidney carcinoma using anti-Cyclin D1 RabMAb (ab40754).
    • Immunohistochemical analysis of paraffin-embedded human hepatocellular carcinoma using anti-Cyclin D1 RabMAb (ab40754).

    References for Anti-Cyclin D1 antibody [EP272Y] (ab40754)

    This product has been referenced in:
    • Wu Y  et al. Low expression of secreted frizzled-related protein 2 and nuclear accumulation of ß-catenin in aggressive nonfunctioning pituitary adenoma. Oncol Lett 12:199-206 (2016). WB ; Human . Read more (PubMed: 27347125) »
    • Wang T  et al. Inhibition of transient receptor potential channel 5 reverses 5-Fluorouracil resistance in human colorectal cancer cells. J Biol Chem 290:448-56 (2015). Read more (PubMed: 25404731) »

    See all 7 Publications for this product

    Product Wall

    Abcam has not validated the combination of species/application used in this Abreview.
    Application Western blot
    Sample Rabbit Tissue lysate - whole (brain)
    Gel Running Conditions Reduced Denaturing
    Loading amount 20 µg
    Specification brain
    Blocking step Milk as blocking agent for 2 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C

    Abcam user community

    Verified customer

    Submitted Aug 19 2016

    Application Immunocytochemistry/ Immunofluorescence
    Sample Human Cell (KMS12, U266, RPMI-8266, Daudi)
    Permeabilization Yes - 0.5% Triton X-100
    Specification KMS12, U266, RPMI-8266, Daudi
    Blocking step Serum as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 10% · Temperature: 25°C
    Fixative Paraformaldehyde

    Ms. Natalie Erdmann

    Verified customer

    Submitted Sep 14 2015

    Abcam guarantees this product to work in the species/application used in this Abreview.
    Application Western blot
    Sample Mouse Tissue lysate - whole (mouse cerebellum)
    Loading amount 20 µg
    Specification mouse cerebellum
    Gel Running Conditions Reduced Denaturing (8%)
    Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 22°C

    Abcam user community

    Verified customer

    Submitted Dec 14 2012